Northeastern University has licensed a tissue-healing nanotechnology to medical device company Audax Medical.
Developed by Thomas Webster of Northeastern’s Department of Chemical Engineering, the innovation is a self-assembling, arginine-rich peptide that is promising for tissue healing and other medical applications. Audax plans to incorporate the technology in its existing tissue regenerative platform.
“We are excited to be collaborating with Northeastern’s team of world-class researchers,” says Audax CEO Mark Johanson. “This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Recent studies show that Webster’s nanotechnology has strong antimicrobial properties against gram-positive bacteria with minimal toxicity to humans.
“We’re very encouraged by initial tests that suggest these nanostructures can accelerate healing and promote targeted cell functions while limiting adverse reactions like inflammation and infection in the body,” says Whitney Herchek, director of R&D Innovation at Audax.
“Nanophase peptides, like the one we recently developed, are of particular interest due to their broad spectrum antimicrobial properties, as well as [their] ability to combat multi-drug resistant bacteria,” comments Webster, who serves as chair of chemical engineering at Northeastern.
In addition to wound care, Audax intends to apply the licensed technology to oral surgery and orthopedic therapy.
Source: PR Newswire